Related Experiment Video
Updated: Mar 29, 2026

An Immature Murine Model of Reversible Unilateral Ureteral Obstruction
Published on: April 4, 2025
Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel
Tetsuya Taniguchi1, Naoki Ashizawa1, Koji Matsumoto1
1Research Laboratories 2, Fuji Yakuhin Co., Ltd., Saitama, Nishi-ku, Japan.
Objectives:
The aim of this study was to establish the rat model for evaluating hypouricemic effects by some uricosuric agents.
Methods:
Rats were made hyperuricemic by subcutaneous administration of potassium oxonate, a uricase inhibitor, or made hypouricemic by oral administration of topiroxostat, a xanthine oxidoreductase inhibitor. Furthermore, rats were co-treated with topiroxostat and inosine, a urate precursor. In each condition, hypouricemic effects by uricosuric agents were examined.
Key Findings:
In potassium oxonate-treated rats, treatment with uricosuric agents such as FYU-981, F12859 and probenecid showed no hypouricemic effect. On the other hand, in topiroxostat-treated rats, uricosuric agents remarkably lowered plasma urate level compared with topiroxostat treatment alone, with a dose dependency of 30 and 100 mg/kg for FYU-981 and F12859 each. The decrease in the plasma urate level observed in the topiroxostat-treated rats disappeared by further co-treatment with inosine.
Conclusions:
Effects of uricosuric agents on the plasma urate level in rats were sensitive to the rate of urate formation. Induction of slower urate formation by topiroxostat provides valuable model for evaluation of hypouricemic effects by uricosuric agents in rats.
Insights
A new rat model using topiroxostat effectively evaluates hypouricemic agents by modulating urate formation. This model is sensitive to urate production rates, offering a valuable tool for drug development.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- Gout and hyperuricemia are linked to elevated plasma urate levels.
- Uricosuric agents aim to reduce plasma urate by increasing its excretion.
- Developing reliable preclinical models is crucial for evaluating hypouricemic drug efficacy.
Purpose of the Study:
- To establish a rat model for assessing the hypouricemic effects of uricosuric agents.
- To investigate the influence of urate formation rate on the efficacy of uricosuric drugs.
- To validate the use of topiroxostat in a preclinical model for gout therapeutics.
Main Methods:
- Rats were induced hyperuricemic using potassium oxonate (uricase inhibitor) or hypouricemic using topiroxostat (xanthine oxidoreductase inhibitor).
- Uricosuric agents (FYU-981, F12859, probenecid) were administered to rats under different conditions.
- Co-administration of topiroxostat with inosine (urate precursor) was performed to assess its impact.
Main Results:
- Uricosuric agents showed no hypouricemic effect in potassium oxonate-induced hyperuricemic rats.
- In topiroxostat-treated rats, uricosuric agents significantly reduced plasma urate levels in a dose-dependent manner.
- Co-treatment with inosine abolished the hypouricemic effect of uricosuric agents in topiroxostat-treated rats.
Conclusions:
- The efficacy of uricosuric agents is influenced by the rate of urate formation.
- Topiroxostat-induced reduction in urate formation creates a suitable model for evaluating hypouricemic agents in rats.
- This model offers a valuable platform for preclinical assessment of drugs targeting hyperuricemia.
More Related Videos
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
07:36Quantitative Real-Time PCR Evaluation of microRNA Expressions in Mouse Kidney with Unilateral Ureteral Obstruction
Published on: August 27, 2020
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi V: Nursing Management
Renal Drug Excretion: Tubular Secretion
Antihypertensive Drugs: Direct Renin Inhibitors
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations